RAREbenzinga

Ultragenyx Submits Biologics License Application To FDA For UX111 AAV Gene Therapy Seeking Accelerated Approval For Sanfilippo Syndrome Type A Treatment

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on December 19, 2024 by benzinga

    Ultragenyx Submits Biologics License Application To FDA For UX111 AAV Gene Therapy Seeking Accelerated Approval For Sanfilippo Syndrome Type A Treatment | RARE Stock News | Candlesense